Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All N‑acetylcysteine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchN-acetylcysteineN-acetylcys.. (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Evaluation of the recovery rate and prevention of hospitalization among covid-19 outpatients: a randomized clinical trial comparing N-acetylcysteine with Bromhexine

Ghayour et al., Research Square, doi:10.21203/rs.3.rs-2309373/v2, IRCT20220302054167N1
Jan 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 93% Improvement Relative Risk Hospitalization 78% Recovery time 16% N-acetylcysteine  Ghayour et al.  EARLY TREATMENT  RCT Is early treatment with N-acetylcysteine beneficial for COVID-19? RCT 150 patients in Iran (April - September 2022) Lower mortality (p=0.013) and hospitalization (p<0.0001) c19early.org Ghayour et al., Research Square, January 2023 FavorsN-acetylcysteine Favorscontrol 0 0.5 1 1.5 2+
14th treatment shown to reduce risk in February 2021
 
*, now with p = 0.000028 from 24 studies, recognized in 3 countries.
Lower risk for mortality, hospitalization, and cases.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19early.org
RCT 225 outpatients in Iran showing lower mortality and hospitalization, and faster recovery with N-acetylcysteine and bromhexine. Baseline information per group is not provided, Figure 1 has the control group hospitalization status switched and the totals do not match, and the registration and previous version of this paper do not include the control group. N-acetylcysteine 600mg daily for 5 days, bromhexine 8mg tid for 5 days.
This study is excluded in meta analysis: inconsistent data, no baseline group details, control group not in previous version.
Study covers N-acetylcysteine and bromhexine.
risk of death, 93.3% lower, RR 0.07, p = 0.01, treatment 0 of 75 (0.0%), control 7 of 75 (9.3%), NNT 11, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of hospitalization, 78.0% lower, RR 0.22, p < 0.001, treatment 11 of 75 (14.7%), control 50 of 75 (66.7%), NNT 1.9.
recovery time, 15.9% lower, relative time 0.84, p = 0.02, treatment mean 12.65 (±0.9) n=75, control mean 15.04 (±8.56) n=75.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ghayour et al., 3 Jan 2023, Randomized Controlled Trial, Iran, preprint, mean age 58.6, 4 authors, study period April 2022 - September 2022, trial IRCT20220302054167N1. Contact: anahitaeslami1995@gmail.com.
This PaperN-acetylcys..All
{ 'institution': [{'name': 'Research Square'}], 'indexed': {'date-parts': [[2024, 3, 3]], 'date-time': '2024-03-03T12:57:56Z', 'timestamp': 1709470676470}, 'posted': {'date-parts': [[2023, 4, 3]]}, 'group-title': 'In Review', 'reference-count': 19, 'publisher': 'Research Square Platform LLC', 'license': [ { 'start': { 'date-parts': [[2023, 4, 3]], 'date-time': '2023-04-03T00:00:00Z', 'timestamp': 1680480000000}, 'content-version': 'unspecified', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'accepted': {'date-parts': [[2022, 11, 24]]}, 'abstract': '<jats:title>Abstract</jats:title>\n' ' <jats:p>Objectives: Due to the referral of COVID-19 patients to outpatient centers in ' 'the early stages, the aim of the present study is to compare the effect of N-acetylcysteine ' 'and Bromhexine on the recovery rate and prevention of hospitalization in outpatients with ' 'COVID-19\n' 'Methodology: This study was conducted from April 2022 to September 2022. First, PCR-confirmed ' 'COVID-19 patients were divided into tree groups, one of these groups received ' 'N-acetylcysteine while the other received bromhexine and One of these groups did not receive ' 'any medication. The patients were followed up on the seventh and fourteenth days of the ' 'disease in terms of the duration of changes in oxygen saturation and recovery. The ' 'hospitalization and death of the patients were also evaluated after one month.\n' 'Results: Out of 225 studied patients, oxygen saturation was increased by 1.33% in the third ' 'visit of the patients who received N-acetylcysteine compared to their first visit. This ' 'percentage was 1.19% in the patients who received bromhexine.29.77% of the patients were ' 'admitted to the hospital and 70.23% of them had no history of hospitalization within 14 day ' 'and their mortality rate was 9.33% in control group and it was zero in both groups of ' 'patients who received drug.\n' 'Conclusions: The results of this study showed that early initiation of Bromhexine and ' 'N-acetylcysteine can effectively reduce the hospitalization rate and mortality and shorten ' 'the duration of hospitalization.\n' 'Clinical trial code: IRCT20220302054167N1 and ethics code: IR.UMSHA.REC.1400.957</jats:p>', 'DOI': '10.21203/rs.3.rs-2309373/v2', 'type': 'posted-content', 'created': {'date-parts': [[2023, 4, 3]], 'date-time': '2023-04-03T19:54:07Z', 'timestamp': 1680551647000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Evaluation of the recovery rate and prevention of hospitalization among covid-19 outpatients: a ' 'randomized clinical trial comparing N-acetylcysteine with Bromhexine', 'prefix': '10.21203', 'author': [ { 'given': 'Anahita Eslami', 'family': 'Ghayour', 'sequence': 'first', 'affiliation': [{'name': 'Hamedan University of medical science'}]}, { 'given': 'Sasan', 'family': 'Nazari', 'sequence': 'additional', 'affiliation': [{'name': 'Hamedan University of medical science'}]}, { 'given': 'Fariba', 'family': 'Keramat', 'sequence': 'additional', 'affiliation': [{'name': 'Hamedan University of medical science'}]}, { 'given': 'Fatemeh', 'family': 'Shahbazi', 'sequence': 'additional', 'affiliation': [{'name': 'Hamedan University of medical science'}]}], 'member': '8761', 'reference': [ { 'issue': '5', 'key': 'ref1', 'doi-asserted-by': 'publisher', 'first-page': '668', 'DOI': '10.1038/s41564-020-0709-x', 'article-title': 'The new scope of virus taxonomy: partitioning the virosphere into 15 ' 'hierarchical ranks', 'volume': '5', 'author': 'International Committee on Taxonomy of Viruses Executive Committee', 'year': '2020', 'unstructured': 'International Committee on Taxonomy of Viruses Executive Committee. The ' 'new scope of virus taxonomy: partitioning the virosphere into 15 ' 'hierarchical ranks. Nat Microbiol. 2020;5(5):668–74. ' 'doi:10.1038/s41564-020-0709-x.', 'journal-title': 'Nat Microbiol'}, { 'key': 'ref2', 'doi-asserted-by': 'publisher', 'first-page': '1047', 'DOI': '10.2147/TCRM.S273700', 'article-title': 'N-Acetylcysteine to Combat COVID-19: An Evidence Review', 'volume': '16', 'author': 'Shi Z', 'year': '2020', 'unstructured': 'Shi Z, Puyo CA. N-Acetylcysteine to Combat COVID-19: An Evidence Review. ' 'Ther Clin Risk Manag. 2020;16:1047–55. doi:10.2147/TCRM.S273700. ' 'Published 2020 Nov 2.', 'journal-title': 'Ther Clin Risk Manag'}, { 'issue': '5', 'key': 'ref3', 'doi-asserted-by': 'publisher', 'first-page': '1058', 'DOI': '10.21037/qims-20-564', 'article-title': 'A systematic review of chest imaging findings in COVID-19', 'volume': '10', 'author': 'Sun Z', 'year': '2020', 'unstructured': 'Sun Z, Zhang N, Li Y, Xu X. A systematic review of chest imaging ' 'findings in COVID-19. Quant Imaging Med Surg. 2020;10(5):1058–79. ' 'doi:10.21037/qims-20-564.', 'journal-title': 'Quant Imaging Med Surg'}, { 'issue': '2', 'key': 'ref4', 'doi-asserted-by': 'publisher', 'first-page': '185', 'DOI': '10.1002/jmv.20255', 'article-title': 'An interferon-gamma-related cytokine storm in SARS patients', 'volume': '75', 'author': 'Huang KJ', 'year': '2005', 'unstructured': 'Huang KJ, Su IJ, Theron M, et al. An interferon-gamma-related cytokine ' 'storm in SARS patients. J Med Virol. 2005;75(2):185–94. ' 'doi:10.1002/jmv.20255.', 'journal-title': 'J Med Virol'}, { 'issue': '2', 'key': 'ref5', 'doi-asserted-by': 'publisher', 'first-page': '168', 'DOI': '10.3390/v11020168', 'article-title': 'Myeloid Cells during Viral Infections and Inflammation', 'volume': '11', 'author': 'Stegelmeier AA', 'year': '2019', 'unstructured': 'Stegelmeier AA, van Vloten JP, Mould RC, et al. Myeloid Cells during ' 'Viral Infections and Inflammation. Viruses. 2019;11(2):168. ' 'doi:10.3390/v11020168. Published 2019 Feb 19.', 'journal-title': 'Viruses'}, { 'issue': '6', 'key': 'ref6', 'doi-asserted-by': 'publisher', 'first-page': '1419', 'DOI': '10.1016/j.cell.2020.08.001', 'article-title': 'Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment', 'volume': '182', 'author': 'Schulte-Schrepping J', 'year': '2020', 'unstructured': 'Schulte-Schrepping J, Reusch N, Paclik D, et al. Severe COVID-19 Is ' 'Marked by a Dysregulated Myeloid Cell Compartment. Cell. ' '2020;182(6):1419–40.e23. doi:10.1016/j.cell.2020.08.001.', 'journal-title': 'Cell'}, { 'issue': '3', 'key': 'ref7', 'doi-asserted-by': 'publisher', 'first-page': '383', 'DOI': '10.1016/j.pcad.2020.02.007', 'article-title': 'Nutraceuticals have potential for boosting the type 1 interferon ' 'response to RNA viruses including influenza and coronavirus', 'volume': '63', 'author': 'McCarty MF', 'year': '2020', 'unstructured': 'McCarty MF, DiNicolantonio JJ. Nutraceuticals have potential for ' 'boosting the type 1 interferon response to RNA viruses including ' 'influenza and coronavirus. Prog Cardiovasc Dis. 2020;63(3):383–5. ' 'doi:10.1016/j.pcad.2020.02.007.', 'journal-title': 'Prog Cardiovasc Dis'}, { 'key': 'ref8', 'doi-asserted-by': 'publisher', 'first-page': '39', 'DOI': '10.1016/j.niox.2020.06.002', 'article-title': 'Tackle the free radicals damage in COVID-19', 'volume': '102', 'author': 'Wu J', 'year': '2020', 'unstructured': 'Wu J. Tackle the free radicals damage in COVID-19. Nitric Oxide. ' '2020;102:39–41. doi:10.1016/j.niox.2020.06.002.', 'journal-title': 'Nitric Oxide'}, { 'issue': '3', 'key': 'ref9', 'doi-asserted-by': 'publisher', 'first-page': 'e1006286', 'DOI': '10.1371/journal.ppat.1006286', 'article-title': 'The NF-κB-dependent and -independent transcriptome and chromatin ' 'landscapes of human coronavirus 229E-infected cells', 'volume': '13', 'author': 'Poppe M', 'year': '2017', 'unstructured': 'Poppe M, Wittig S, Jurida L, et al. The NF-κB-dependent and -independent ' 'transcriptome and chromatin landscapes of human coronavirus ' '229E-infected cells. PLoS Pathog. 2017;13(3):e1006286. ' 'doi:10.1371/journal.ppat.1006286. Published 2017 Mar 29.', 'journal-title': 'PLoS Pathog'}, { 'key': 'ref10', 'doi-asserted-by': 'publisher', 'author': 'Rumack BH', 'year': '2021', 'unstructured': 'Rumack BH, Bateman DN. Acetaminophen and acetylcysteine dose and ' 'duration: past, present and future [published correction appears in Clin ' 'Toxicol (Phila). 2021 Apr;59(4):359] [published correction appears in ' 'Clin Toxicol (Phila). 2021 Dec;59(12):1195]. ClinToxicol(Phila).2012; ' '50(2):91–98. doi:10.3109/15563650.2012.659252.', 'DOI': '10.3109/15563650.2012.659252'}, { 'issue': '5', 'key': 'ref11', 'doi-asserted-by': 'publisher', 'first-page': '1229', 'DOI': '10.3904/kjim.2019.105', 'article-title': 'N-acetylcysteine decreases airway inflammation and responsiveness in ' 'asthma by modulating claudin 18 expression', 'volume': '35', 'author': 'Lee PH', 'year': '2020', 'unstructured': 'Lee PH, Hong J, Jang AS. N-acetylcysteine decreases airway inflammation ' 'and responsiveness in asthma by modulating claudin 18 expression. Korean ' 'J Intern Med. 2020;35(5):1229–37. doi:10.3904/kjim.2019.105.', 'journal-title': 'Korean J Intern Med'}, { 'key': 'ref12', 'doi-asserted-by': 'publisher', 'author': 'Šalamon Š', 'year': '2019', 'unstructured': 'Šalamon Š, Kramar B, Marolt TP, Poljšak B, Milisav I. Medical and ' 'Dietary Uses of N-Acetylcysteine. Antioxidants (Basel). 2019;8(5):111. ' 'Published 2019 Apr 28. doi:10.3390/antiox8050111.', 'DOI': '10.3390/antiox8050111'}, { 'issue': '7', 'key': 'ref13', 'first-page': '633', 'article-title': 'Use of N-acetylcysteine in the management of coronary artery diseases', 'volume': '44', 'author': 'Marchetti G', 'year': '1999', 'unstructured': 'Marchetti G, Lodola E, Licciardello L, Colombo A. Use of ' 'N-acetylcysteine in the management of coronary artery diseases. ' 'Cardiologia. 1999;44(7):633–7.', 'journal-title': 'Cardiologia'}, { 'issue': '1', 'key': 'ref14', 'doi-asserted-by': 'publisher', 'first-page': '190', 'DOI': '10.1378/chest.105.1.190', 'article-title': 'N-acetylcysteine enhances recovery from acute lung injury in man. A ' 'randomized, double-blind, placebo-controlled clinical study', 'volume': '105', 'author': 'Suter PM', 'year': '1994', 'unstructured': 'Suter PM, Domenighetti G, Schaller MD, Laverrière MC, Ritz R, Perret C. ' 'N-acetylcysteine enhances recovery from acute lung injury in man. A ' 'randomized, double-blind, placebo-controlled clinical study. Chest. ' '1994;105(1):190–4. doi:10.1378/chest.105.1.190.', 'journal-title': 'Chest'}, { 'key': 'ref15', 'doi-asserted-by': 'publisher', 'first-page': '319', 'DOI': '10.1186/s12879-022-07312-7', 'article-title': 'Demographics, clinical characteristics, and outcomes of 27,256 ' 'hospitalized COVID-19 patients in Kermanshah Province, Iran: a ' 'retrospective one-year cohort study', 'volume': '22', 'author': 'Hesni E', 'year': '2022', 'unstructured': 'Hesni E, Sayad B, Shadmani K. F. et al. Demographics, clinical ' 'characteristics, and outcomes of 27,256 hospitalized COVID-19 patients ' 'in Kermanshah Province, Iran: a retrospective one-year cohort study. BMC ' 'Infect Dis. 2022;22:319. doi.org/10.1186/s12879-022-07312-7.', 'journal-title': 'BMC Infect Dis'}, { 'issue': '1', 'key': 'ref16', 'doi-asserted-by': 'publisher', 'first-page': '368504221074574', 'DOI': '10.1177/00368504221074574', 'article-title': 'Use of N-Acetylcysteine at high doses as an oral treatment for patients ' 'hospitalized with COVID-19', 'volume': '105', 'author': 'Izquierdo JL', 'year': '2022', 'unstructured': 'Izquierdo JL, Soriano JB, González Y, et al. Use of N-Acetylcysteine at ' 'high doses as an oral treatment for patients hospitalized with COVID-19. ' 'Sci Prog. 2022;105(1):368504221074574. doi:10.1177/00368504221074574.', 'journal-title': 'Sci Prog'}, { 'issue': '4', 'key': 'ref17', 'doi-asserted-by': 'publisher', 'first-page': '209', 'DOI': '10.34172/bi.2020.27', 'article-title': 'Effect of bromhexine on clinical outcomes and mortality in COVID-19 ' 'patients: A randomized clinical trial', 'volume': '10', 'author': 'Ansarin K', 'year': '2020', 'unstructured': 'Ansarin K, Tolouian R, Ardalan M, et al. Effect of bromhexine on ' 'clinical outcomes and mortality in COVID-19 patients: A randomized ' 'clinical trial. Bioimpacts. 2020;10(4):209–15. doi:10.34172/bi.2020.27.', 'journal-title': 'Bioimpacts'}, { 'key': 'ref18', 'unstructured': 'JohnsHopkins Coronavirus Resource Center (CRC). (2022) ' 'Https://coronavirus.jhu.edu/data/mortality.'}, { 'issue': '6', 'key': 'ref19', 'doi-asserted-by': 'publisher', 'first-page': '1650', 'DOI': '10.1007/s43440-021-00296-2', 'article-title': 'A pilot study on intravenous N-Acetylcysteine treatment in patients ' 'with mild-to-moderate COVID19-associated acute respiratory distress ' 'syndrome', 'volume': '73', 'author': 'Taher A', 'year': '2021', 'unstructured': 'Taher A, Lashgari M, Sedighi L, Rahimi-Bashar F, Poorolajal J, Mehrpooya ' 'M. A pilot study on intravenous N-Acetylcysteine treatment in patients ' 'with mild-to-moderate COVID19-associated acute respiratory distress ' 'syndrome. Pharmacol Rep. 2021 Dec;73(6):1650–9. ' 'doi:10.1007/s43440-021-00296-2. Epub 2021 Jun 10. PMID: 34114174; PMCID: ' 'PMC8191712.', 'journal-title': 'Pharmacol Rep'}], 'container-title': [], 'original-title': [], 'link': [ { 'URL': 'https://www.researchsquare.com/article/rs-2309373/v2', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.researchsquare.com/article/rs-2309373/v2.html', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 5, 23]], 'date-time': '2023-05-23T18:44:17Z', 'timestamp': 1684867457000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.researchsquare.com/article/rs-2309373/v2'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 4, 3]]}, 'references-count': 19, 'URL': 'http://dx.doi.org/10.21203/rs.3.rs-2309373/v2', 'relation': { 'is-version-of': [ { 'id-type': 'doi', 'id': '10.21203/rs.3.rs-2309373/v1', 'asserted-by': 'subject'}, { 'id-type': 'doi', 'id': '10.21203/rs.3.rs-2309373/v3', 'asserted-by': 'subject'}, { 'id-type': 'doi', 'id': '10.21203/rs.3.rs-2309373/v4', 'asserted-by': 'subject'}], 'has-version': [ { 'id-type': 'doi', 'id': '10.21203/rs.3.rs-2309373/v3', 'asserted-by': 'object'}, { 'id-type': 'doi', 'id': '10.21203/rs.3.rs-2309373/v1', 'asserted-by': 'object'}, { 'id-type': 'doi', 'id': '10.21203/rs.3.rs-2309373/v4', 'asserted-by': 'object'}]}, 'subject': [], 'published': {'date-parts': [[2023, 4, 3]]}, 'subtype': 'preprint'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit